Glenmark Pharmaceuticals Limited Overview
Pro stress-test →Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, founded in 1977. The company develops, manufactures, and sells generics, specialty medicines, and over the counter pharmaceutical products across India, North America, Europe, and internationally. Glenmark focuses on developing products in respiratory, dermatology, and oncology therapy areas.
Strategic Profile
Pro stress-test →The company reported consolidated revenue growth of 15.1% year-over-year for Q3 FY26, with significant contributions from the India formulation business which grew by 22.1%. Glenmark launched innovative products including NEBZMART GFB Smartules and Glenmark AIRZ FB Smartules, marking the world's first nebulized fixed-dose triple therapy for COPD. The company's Monroe manufacturing site is scheduled to begin commercial production in Q4 FY26, supporting its systematic regulatory filing strategy in the North American generic pharmaceuticals market.
Competitive Landscape
Pro stress-test →Glenmark competes across multiple therapeutic areas including dermatology, respiratory, oncology, and specialty generics. The company faces competition from global pharma giants and regional Indian pharmaceutical manufacturers. Its differentiation lies in complex injectables, respiratory products, and dermatology innovation, though regulatory challenges present competitive vulnerabilities.
Industry Context
Glenmark Pharmaceuticals Limited operates in Pharmaceuticals - Generics, Specialty & Innovative Medicines.
Key facts
Founded: 1977 · Headquarters: Mumbai, India · Employees: 12,736 · Revenue: $1.25B+ (FY2017, recent figures in INR) · Market cap: $6.6B